The Long Run with Luke Timmerman

1. Ep213: Daphne Koller on The Moment in AI Drug Discovery

   03.11.20261 Std. 4 Min.Als Nächstes

   Daphne Koller, founder and CEO of South San Francisco-based Insitro, on the moment in AI drug discovery.

2. Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines

   23.10.20261 Std. 15 Min.Als Nächstes

   Tim Shannon is a general partner at Canaan Partners, and a founding executive at a pair of targeted protein degrader companies -- Arvinas and Halda Therapeutics.

3. Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience

   07.10.20261 Std. 7 Min.Als Nächstes

   Arden Patapoutian, professor of neuroscience at Scripps Research and Howard Hughes Medical Institute, on new discoveries in neuroscience related to our sense of touch, pain, and more.

4. Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders

   23.09.20261 Std. 4 Min.Als Nächstes

   Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.

5. Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets

   09.09.20261 Std. 36 Min.Als Nächstes

   Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.

6. Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus

   25.08.20261 Std. 7 Min.Als Nächstes

   Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.

7. Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases

   11.08.20261 Std. 18 Min.Als Nächstes

   Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.

8. Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases

   28.07.20261 Std. 7 Min.Als Nächstes

   Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.

9. Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With

   14.07.20261 Std. 8 Min.Als Nächstes

   Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.

10. Ep204: Troy Wilson on Precision Cancer Drugs and Combos

    30.06.20261 Std. 7 Min.Als Nächstes

    Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.

11. Ep203: Sri Kosuri on Small Molecule Correctors of Disease

    16.06.20261 Std. 12 Min.Als Nächstes

    Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases.

12. Ep202: Becky Pferdehirt on Reimagining Science for the AI Era

    02.06.20261 Std. 8 Min.Als Nächstes

    Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.

13. Ep201: Jeremy Levin on Biotech in the Balance

    19.05.20261 Std. 9 Min.Als Nächstes

    Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."

14. Ep200: Richard Pops Reflects on a 35-Year Career in Biotech

    05.05.20261 Std. 14 Min.Als Nächstes

    Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.

15. Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era

    21.04.20261 Std. 10 Min.Als Nächstes

    Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.

16. Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery

    07.04.20261 Std. 17 Min.Als Nächstes

    Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.

17. Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature

    31.03.20261 Std. 17 Min.Als Nächstes

    Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.

18. Ep196: Otello Stampacchia on Europe's Biotech Crisis

    17.03.20261 Std. 3 Min.Als Nächstes

    Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.

19. Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases

    03.03.20261 Std. 6 Min.Als Nächstes

    Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.

20. Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery

    17.02.20261 Std. 9 Min.Als Nächstes

    Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report

21. Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines

    22.01.20261 Std. 5 Min.Als Nächstes

    Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.

22. Ep192: Kate Haviland on Following the Science to Precision Immunology

    08.01.20261 Std. 26 Min.Als Nächstes

    Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

23. Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

    15.12.20251 Std. 8 Min.Als Nächstes

    Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

24. Ep190: Neil Kumar on Building a Rare Disease Drug Company

    20.11.20251 Std. 13 Min.Als Nächstes

    Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

25. Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI

    12.11.20251 Std. 13 Min.Als Nächstes

    Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.

26. Ep188: Art Krieg on Innate Immune System Activators for Cancer

    28.10.20251 Std. 9 Min.Als Nächstes

    Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.

27. Ep187: Eric Fischer on Creating a New Class of Medicines

    14.10.20251 Std. 6 Min.Als Nächstes

    Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.

28. Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope

    29.09.20251 Std. 3 Min.Als Nächstes

    Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.

29. Ep185: Dr. Lachelle Weeks on Predicting Leukemia Risk At Scale

    17.09.20251 Std. 6 Min.Als Nächstes

    Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.

30. Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies

    28.08.20251 Std. 50 Min.Als Nächstes

    Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.

Hier stehen die neuesten 40 von 211 Folgen. Ältere Folgen findest du im Feed des Podcasts.